{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-020220","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.711722+00:00","generated_at":"2026-06-19T13:30:18.019197+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Aytu BioPharma enters amended employment agreements with CEO Josh Disbrow and CFO Mark Oki","bullets":["CEO Disbrow’s agreement amended to one-year terms with auto-renewal; change of control acceleration requires termination within 12 months.","CFO Oki’s agreement modified to conform equity acceleration and Cause definition changes including willful malfeasance standard.","Cause definitions revised across both agreements: willful malfeasance/willful misconduct replaces material misconduct and gross negligence.","Both amendments supersede prior employment agreements; terms approved by Compensation Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-020220","json":"https://secwatch.observer/filing/0001104659-23-020220.json","markdown":"https://secwatch.observer/filing/0001104659-23-020220.md","text":"https://secwatch.observer/filing/0001104659-23-020220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923020220/0001104659-23-020220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923020220/tm236705d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:30:18.019197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}